Search Results for “EC” – Page 596 – media

Do You Really Need To Stop Drinking On Antibiotics?

First, it's important to remember why you’re on antibiotics to begin with: You feel awful and, with some help from your prescription, your body is working to fight off a nasty bacterial infection. (Antibiotics cannot treat anything viral, like a flu.)
- Source: womenshealthmag
- 506
- November 29, 2017
antibiotics Researches
Radiotherapy-resistant tumors could be defeated with experimental drugs

It may be possible to use drugs that are already in development to overcome radiotherapy resistance in tumors, which is often a major barrier to the successful treatment of many cancers.
- Source: medicalnewstoday
- 539
- November 28, 2017
cancer radiotherapy Researches tumor
Are Antipsychotics Used Appropriately for Managing Dementia?

A study reviews data on the indications for use of antipsychotics in elderly patients with dementia across four clinical settings in Canada.
- Source: medicalnewsbulletin
- 522
- November 28, 2017
antipsychotics Dementia Researches
Zika Virus Kills Brain Cancer Stem Cells MEDICINE & HEALTH

While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St. Louis and the University of California San Diego School of Medicine shows that the virus kills brain cancer stem cells, the kind of cells most resistant to standard treatments.
- Source: scienmag
- 569
- November 28, 2017
brain cancer glioblastoma Researches
Bay Area’s Medeor Therapeutics Bags $57M

Medeor Therapeutics announced it had closed on an oversubscribed Series B financing worth $57 million. The round was led by RA Capital Management. New investors included Sofinnova Ventures and 6 Dimensions Capital. They were joined by existing investors Vivo Capital and WuXi Healthcare Ventures.
- Source: Biospace
- 615
- November 28, 2017
cellular immunotherapies Market Views Series
Medical Products for Human Use

New technologies, therapies and medicines are emerging; this includes regenerative medicine, more personalised treatments, as well as the development of nanomedicines. The Commission is committed to monitoring scientific progress and to constantly review Community legislation in the light of new developments so as to make safe, novel treatments available to patients as early as possible.
- Source: ec.europa.eu
- 629
- November 28, 2017
nanomedicine polices regenerative medicine
Prometic Reports Positive Interim Clinical Data From Ongoing Intravenous Immunoglobulin Pivotal Phase III Trial

Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) announced positive interim six-month clinical data from its ongoing pivotal IVIG Phase 3 clinical trial in patients suffering from primary immunodeficiencies (PID) following review of the data by the Data Safety Monitoring Board (DSMB), which confirmed no significant safety issues and that efficacy appeared to be comparable to existing commercial IVIG products.
- Source: Prometic
- 496
- November 28, 2017
Clinical Trials IVIG PID
Unforeseen new drug target discovered for acute myeloid leukemia

A study has found an unexpected new drug target for acute myeloid leukaemia (AML) that could open new avenues to develop effective treatments against this potentially lethal disease. Researchers from the Wellcome Trust Sanger Institute, the Gurdon Institute and their collaborators show that inhibiting the METTL3 gene destroys human and mouse AML cells without harming non-leukaemic blood cells.
- Source: medicalxpress
- 571
- November 28, 2017
AML blood cancer Chemotherapy leukaemia Researches
How Does Schizophrenia Change Brain Structures?

Researchers compare the volumes of various regions of the brain in people with and without schizophrenia to identify the key brain structures involved.
- Source: medicalempires
- 514
- November 27, 2017
brain Researches schizophrenia
European Commission Approves TREMFYA® (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

Janssen-Cilag International NV announced that the European Commission (EC) has approved TREMFYA® (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Guselkumab is the first biologic that selectively blocks interleukin (IL)-23, a key driver of the immune inflammatory response in psoriasis.
- Source: Prnewswire
- 454
- November 27, 2017
interleukin Market Views plaque psoriasis TREMFYA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.